CINGULATE -CW23(NASDAQ:CINGW) stock News

CINGW Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Cingulate Inc. - Mentions: CING

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

2 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

2 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Provides Management Team Update

3 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

3 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate Inc. to Present at the LD Micro Main Event XVI

6 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

7 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

7 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

7 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

8 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

10 months ago - By: Cingulate Inc. - Mentions: CING

Final Study Completed for Cingulate’s Lead Asset CTx-1301

10 months ago - By: Cingulate Inc. - Mentions: CING

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate to Participate in Benzinga All Live Access Event

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate Announces Adjournment of Special Meeting

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

a year ago - By: Cingulate Inc. - Mentions: CING

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

1 years ago - By: Cingulate Inc. - Mentions: CING

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate to Participate in Benzinga All Live Access Event

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate to Attend DCAT Week 2024 in New York City

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate Announces Closing of $7.5 Million Public Offering

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate Announces Pricing of $7.5 Million Public Offering

2 years ago - By: Cingulate Inc. - Mentions: CING

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

2 years ago - By: Cingulate Inc. - Mentions: CING

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate to Host CNS Key Opinion Leader Panel in New York City

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate Announces Closing of $4.0 Million Public Offering

2 years ago - By: Cingulate Inc. - Mentions: CING

Cingulate Announces Pricing of $4.0 Million Public Offering

2 years ago - By: Cingulate Inc. - Mentions: CING

CINGULATE -CW23 (CINGW) Stock News

CINGW Latest News, Press Relases and Analysis